Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Agility Robotics Goes Public on Nasdaq: What the Robotics Industry Can Teach About 3D Data Visualization

Agility Robotics goes public on Nasdaq: What the robotics debate on 3D data visualization teaches Agility Robotics, the US market leader in the provision of humanoid robots, has gone public on Nasdaq. Ars Technica puts it precisely: The move invites critical examination of the humanoid robot market. New markets need skepticism. This skepticism is a good occasion for a…

Translated from German Read in German

Agility Robotics, a US-based provider of humanoid robots, has been listed on the Nasdaq stock exchange. This development has sparked a critical examination of the humanoid robot market. The article also discusses the limitations of 2D data visualization in fields such as bioinformatics and introduces NexoPeek, a virtual reality laboratory for exploring molecular structures in 3D. NexoPeek allows users to interact with proteins in a immersive environment, providing a new way to understand complex biological concepts.

Written by urgent.news from Dev.to's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.

Read the original at dev.to →

More in Finance & Markets

Is Broadcom a Buy After Falling 9% in One Day?

The recent drop in Broadcom stock does not align with its fundamentals.

  • Broadcom stock fell 9% due to AI fears in October
  • AI semiconductor revenue surged 143%, accounting for 50% of sales
  • Broadcom projects $115 billion AI semiconductor revenue for fiscal 2026 Q3

Puma: 3 Key Takeaways for Long-Term Investors

Puma's U.S. NERLYNX demand is heading toward a second year of growth, yet China royalties are shrinking, a split the company must balance.

  • Puma paid off remaining loan to Athyrium, gaining $108.5M liquidity for R&D
  • Lowered royalty guidance for NERLYNX due to generic market share rise in China
  • Promising ALISCA-Breast1 trial results lead to planned phase III study in 2027

More from Sunday 8 November →